Patents Examined by Kamal Saeed
  • Prodigiosin analogs and methods of use
    Patent number: 11993589
    Abstract: Prodigiosin analogs which reactivate the p53 pathway are provided, as well as compositions of these compounds, and methods for reactivation of the p53 pathway using these compounds are provided. The prodigiosin analogs may be used to treat cancer in which p53 mutation plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.
    Type: Grant
    Filed: December 7, 2022
    Date of Patent: May 28, 2024
    Assignee: Institute For Cancer Research
    Inventors: Wafik S. El-Deiry, Xiaobing Tian
  • 4,4-divinylazoarylene-bridged diruthenium complex bearing Ru(CO)Cl(PiPr3)2 as an inorganic catalyst
    Patent number: 11986809
    Abstract: A 4,4?-divinylazoarylene-bridged diruthenium complex bearing two Ru(CO)Cl(PiPr3)2 moieties, its synthesis, and its use as an catalyst in organic processes.
    Type: Grant
    Filed: November 14, 2023
    Date of Patent: May 21, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Obadah S. Abdel-Rahman, Mohamed Shaker S. Adam
  • 4,4?-divinylazobenzene-bridged diruthenium complex bearing Ru(CO)Cl(PPr)moieties as an inorganic catalyst
    Patent number: 11980877
    Abstract: A 4,4?-divinylazobenzene-bridged diruthenium complex bearing two Ru(Co)Cl(PiPr3)2 moieties, its synthesis, and its use as an catalyst in organic processes.
    Type: Grant
    Filed: November 13, 2023
    Date of Patent: May 14, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventor: Obadah S. Abdel-Rahman
  • Neuroprotective compositions and methods of using the same
    Patent number: 11974988
    Abstract: This invention is directed to neuroprotective compositions and methods of using the same to treat neurodegenerative diseases.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: May 7, 2024
    Assignees: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jeffrey Erickson, Heike Wulff, Heesung Shim, Vikrant Singh, Latika Singh
  • Remdesivir treatment methods
    Patent number: 11975012
    Abstract: Provided herein are methods of treating or preventing a viral infection in a subject comprising administering a compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, wherein the subject is not being treated with chloroquine, or an analog or salt thereof.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: May 7, 2024
    Assignee: Gilead Sciences, Inc.
    Inventor: Tomas Cihlar
  • 3-(4-chlorophenyl)-5-{[5-methyl-2-(propan-2-yl)phenoxy]methyl }- 1,2,4-oxadiazole as an antitumor and antimicrobial compound
    Patent number: 11970471
    Abstract: A compound 3-(4-chlorophenyl)-5-{[5-methyl-2-(propan-2-yl)phenoxy]methyl}-1,2,4-oxadiazole compound, its synthesis, and its use as an anticancer and/or antimicrobial agent.
    Type: Grant
    Filed: December 26, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer, Sahar M. Mohamed, Mohammad Mahboob Alam
  • Inhibitor of indoleamine-2,3-dioxygenase (IDO)
    Patent number: 11969425
    Abstract: The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating a disease associated with IDO, for example, cancer or an infectious disease (e.g., viral or bacterial infectious diseases). Also, provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
    Type: Grant
    Filed: February 9, 2023
    Date of Patent: April 30, 2024
    Assignee: INVENTISBIO LLC
    Inventors: Xing Dai, Yaolin Wang
  • Deuterated compounds for restoring mutant p53 function
    Patent number: 11963953
    Abstract: The compounds of the current disclosure include propynyl substituted indoles, where one or more hydrido radicals is substituted with a deuterium atom, wherein the compound binds a mutant p53 protein and increases wild-type p53 activity of the mutant p53 protein.
    Type: Grant
    Filed: January 26, 2023
    Date of Patent: April 23, 2024
    Assignee: PMV Pharmaceuticals, Inc.
    Inventor: Binh Vu
  • Thyroid hormone receptor agonists and uses thereof
    Patent number: 11964964
    Abstract: Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with thyroid hormone receptor activity. The methods and compositions disclosed herein include the use of at least one thyroid hormone receptor agonist.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: April 23, 2024
    Assignee: XIZANG HAISCO PHARMACEUTICAL CO., LTD.
    Inventors: Bohan Jin, Gene Hung, Qing Dong
  • Compounds useful for inhibiting RET kinase
    Patent number: 11964968
    Abstract: Provided herein are RET kinase inhibitors according to the formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods for their use in the treatment of diseases that can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. A, R1, n, X1, X2, X3, X4, and R2 have the meanings given in the specification.
    Type: Grant
    Filed: February 6, 2023
    Date of Patent: April 23, 2024
    Assignee: ELI LILLY AND COMPANY
    Inventors: Erin D. Anderson, Steven W. Andrews, Kevin R. Condroski, Thomas C. Irvin, Gabrielle R. Kolakowski, Manoj Kumar, Elizabeth A. McFaddin, Megan McKenney, Michael J. Munchhof, Michael B. Welch
  • Pharmaceutical composition for preventing or treating alopecia areata acting as a functional antagonist for S1PR1 and S1PR4
    Patent number: 11957665
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating alopecia areata acting as a functional antagonist for S1P receptor's subtypes S1PR1 and S1PR4, and more particularly, relates to a pharmaceutical composition containing as an active ingredient a sphingolipid compound acting as a functional antagonist for S1PR1 and S1PR4, does not cause cardiovascular side effects, and is effective in preventing or treating alopecia areata.
    Type: Grant
    Filed: September 26, 2023
    Date of Patent: April 16, 2024
    Assignee: NEXTGEN BIOSCIENCE CO., LTD.
    Inventors: Bong Yong Lee, Yang Hae Park, Eun Jeong Kim
  • Compounds and methods for regulating, limiting, or inhibiting expression
    Patent number: 11957682
    Abstract: In one aspect, the disclosure relates to compounds useful to regulate, limit, or inhibit the expression of AVIL (advillin), methods of making same, pharmaceutical compositions comprising same, and methods of treating disorders associated with AVIL dysregulation using same. In aspects, the disclosed compounds, compositions and methods are useful for treating disorders or diseases in which the regulation, limitation, or inhibition of the expression of AVIL can be clinically useful, such as, for example, the treatment of cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
    Type: Grant
    Filed: June 27, 2022
    Date of Patent: April 16, 2024
    Assignee: University of Virginia Patent Foundation
    Inventors: Hui Li, Zhongqiu Xie
  • Modulators of Kv3 channels to treat pain
    Patent number: 11944623
    Abstract: The present invention provides a modulator of Kv3.1 and/or Kv3.2 and/or Kv3.3 channels for use in the prophylaxis or treatment of pain.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: April 2, 2024
    Assignee: AUTIFONY THERAPEUTICS LIMITED
    Inventors: Charles Large, Giuseppe Alvaro
  • Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders
    Patent number: 11939324
    Abstract: The present invention relates to a compound of formula (I) or a tautomer thereof, wherein R1, R2, R3, R4 and R5, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of epilepsy and/or neurodegenerative diseases.
    Type: Grant
    Filed: November 22, 2022
    Date of Patent: March 26, 2024
    Assignees: reMYND N.V., Katholieke Universiteit Leuven
    Inventors: Johan Gerard Griffioen, Katrien Princen, Tom Francois L. Van Dooren, Arnaud Didier Marie Marchand, Amuri Kilonda, Sara Allasia, Patrick Chaltin
  • Amide compounds and method for making and using
    Patent number: 11939317
    Abstract: Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Grant
    Filed: November 9, 2022
    Date of Patent: March 26, 2024
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Kin Tso, Hui Li, Yan Chen, Rose Yen, Vanessa Taylor, Thilo Heckrodt, Rajinder Singh, Simon Shaw
  • Pyrrolidinyl urea derivatives and application thereof in TrkA-related diseases
    Patent number: 11932652
    Abstract: The present invention relates to a class of TrkA inhibitors and an application thereof in the preparation of a drug for the treatment of diseases associated with TrkA. The present invention specifically discloses compounds represented by formula (I) and formula (II), tautomer thereof or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: March 19, 2024
    Assignee: ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD.
    Inventors: Yang Zhang, Wentao Wu, Zhixiang Li, Jian Qin, Jie Li, Zhen Gong, Jian Li, Shuhui Chen
  • Process for preparing aficamten
    Patent number: 11932631
    Abstract: Provided herein is a process for the preparation of (R)—N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide, intermediates thereof, and salts of the foregoing.
    Type: Grant
    Filed: August 2, 2022
    Date of Patent: March 19, 2024
    Assignee: CYTOKINETICS, INC.
    Inventors: Denise Andersen, Matthew Pfeiffer, Norma Tom, Bradley P. Morgan
  • Sphingosine pathway modulating compounds for the treatment of coronavirus infection
    Patent number: 11931344
    Abstract: The invention provides methods and compositions for treating a coronavirus infection using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
    Type: Grant
    Filed: January 11, 2023
    Date of Patent: March 19, 2024
    Assignee: ENZO BIOCHEM, INC.
    Inventor: Elazar Rabbani
  • Uses of 4?-desferrithiocin analogs
    Patent number: 11931346
    Abstract: Macular degeneration, closed head injury, stroke, irritable bowel disease, and reperfusion injury are all associated with biological injury due to reactive oxygen species, probably due to focal iron overload in many instances. The present invention provides methods and pharmaceutical compositions for treating these diseases and conditions using desferrithiocin analogs of Formula (I). In certain embodiments, the analogs include a poly ether moiety at the 4?-position of the phenyl ring of the compound.
    Type: Grant
    Filed: May 14, 2021
    Date of Patent: March 19, 2024
    Assignee: University of Florida Research Foundation, Incorporated
    Inventor: Raymond J. Bergeron, Jr.
  • Solid dosage form having excellent stability
    Patent number: 11925648
    Abstract: The present invention provides a solid dosage form having good stability, suspensibility in water and fluidity by preparing a solid dosage form containing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a stabilizer, a sugar alcohol and/or a sugar, a water-soluble polymer and an inorganic substance.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: March 12, 2024
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Naoya Mizutani, Masayuki Morimoto, Maki Okabe, Masaaki Ito, Go Kimura